Compare PACK & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | MRVI |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | 415 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | PACK | MRVI |
|---|---|---|
| Price | $3.60 | $7.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $7.08 | ★ $8.50 |
| AVG Volume (30 Days) | 537.2K | ★ 2.2M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $395,000,000.00 | $185,743,000.00 |
| Revenue This Year | $9.87 | $14.01 |
| Revenue Next Year | $9.00 | $6.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $3.22 | $2.55 |
| 52 Week High | $7.81 | $9.42 |
| Indicator | PACK | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 47.36 |
| Support Level | $3.29 | $6.41 |
| Resistance Level | $3.82 | $7.60 |
| Average True Range (ATR) | 0.18 | 0.54 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 37.65 | 28.51 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.